Hycamtin

Hycamtin is the brand name for the oral formulation of topotecan, a topoisomerase I inhibitor used as an antineoplastic agent. It is supplied in the European market as a prescription‑only product. The medication is administered by mouth and belongs to the ATC class L01XX02. Hycamtin works by interfering with DNA replication in cancer cells, leading to cell death. The drug is indicated for several tumours and is prescribed by oncologists.

Hycamtin is used as part of chemotherapy regimens for certain adult cancers where topoisomerase I inhibition is appropriate.

- Ovarian cancer, typically administered after prior platinum‑based therapy. - Small cell lung cancer, used in patients with extensive‑stage disease. - Cervical cancer, indicated for recurrent or metastatic disease. - Endometrial cancer, employed when standard hormonal therapy has failed. - Other solid tumours, such as breast or colorectal cancer, in off‑label clinical trials. - Combination regimens, often paired with cisplatin, carboplatin, or paclitaxel.

Adverse reactions to Hycamtin vary in frequency and severity, reflecting its impact on both cancerous and normal rapidly dividing cells.

Common: - Nausea and vomiting. - Diarrhea or constipation. - Fatigue and weakness. - Decreased blood counts such as mild neutropenia or anemia.

Serious: - Febrile neutropenia or severe infection. - Thrombocytopenia leading to bleeding. - Severe allergic reactions including anaphylaxis.

Because Hycamtin can affect bone marrow and other organ systems, several precautions should be observed before and during therapy.

- Assess complete blood count prior to each cycle. - Monitor renal and hepatic function regularly. - Avoid use in pregnancy; category D, advise effective contraception. - Adjust dose in patients with impaired renal function. - Counsel patients about signs of infection or bleeding. - Review concomitant medications that may suppress marrow. - Use caution in elderly patients due to increased toxicity risk.

Hycamtin may interact with other medicines that influence its metabolism or bone‑marrow toxicity, requiring careful management.

Avoid: - Concurrent use of other myelosuppressive chemotherapy agents (e.g., cyclophosphamide, ifosfamide). - Strong CYP3A4 inducers that could reduce exposure (e.g., rifampin, carbamazepine).

Use with caution: - Antiemetics such as ondansetron that may prolong QT interval. - Drugs that affect renal clearance (e.g., NSAIDs, aminoglycosides). - Live vaccines due to immunosuppression risk. - Hormonal contraceptives may have reduced efficacy.